Filter content by tags:
Patient cases
Speaker: Jesper Palshof
Date: June 2024
Tags: Patient cases
How to optimize Cabozantinib
Speaker: Niels Fristrup
Date: 24 November 2024
Tags: Treatment timing, optimization and patient stratification
Optimal treatment for patients in favorable IMDC risk group
Speaker: Daniel Heinrich and Katriina Jalkanen
Date: 1st December 2023
Tags: Nordic RCC Summit 2023,Ā First line systemic therapy
Non-drug options in oligometastatic RCC
Speaker: Panu Jaakkola
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape
Approaches to treatment of oligoprogressive disease, Patient case and discussion
Speaker: Jesper Andreas Palshof
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape
nccRCC ā Should we change our practice?
Speaker: Katarina Puco
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape
Management of specific drug toxicities: The Immunotoxicity Clinic
Speaker: Jesper Andreas Palshof
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, AE management
Cytoreductive nephrectomy in advanced RCC ā Praxis in Sweden
Speaker: Fabian Hofmann
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery
Cytoreductive nephrectomy in advanced RCC ā Praxis in Norway
Speaker: Karin Margrete Hjelle
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery
To cut or not to cut: The role of cytoreductive nephrectomy in advanced RCC
Speaker: Arnaud Mejean
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery
Cytoreductive Nephrectomy in advanced RCC ā Praxis in Denmark
Speaker: Anna Krarup Keller
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery
Adjuvant treatment in RCC ā Status in the Nordics ā Sweden
Speaker: Magnus Lindskog
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment
Adjuvant treatment in RCC ā Status in the Nordics ā Norway
Speaker: Katarina Puco
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment
Adjuvant treatment in RCC ā Status in the Nordics ā Denmark
Speaker: Niels Fristrup
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment
Adjuvant treatment in RCC
Speaker: Axel Bex
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment
Njurcancer: De vanligaste och kliniskt viktigaste typerna och deras sardrag med fokus pa behandling och prognos
Speaker: Dr Martin Johansson (Swedish only)
Date: 21 September 2023
Tags: Pathology
Kostbehandling vid diarre under onkologisk behandling
Speaker: Leg dietist Maria Berglund, leg dietist Klinisk Nutrition, Akademiska Sjukhuset (Swedish only)
Date: 21 September 2023
Tags: AE management
1st line therapy for metastatic renal cell carcinoma
Speaker: Prof. Dr. Jonas Busch, Department of Urology, Berlin Vivantes Klinikum Am Urban & Im Friedrichshain
Date: 25 May 2023
Tags: Treatment landscape
IO/IO vs IO/TKI in frontline setting mRCC ā Pros and Cons
Speaker: Daniel Heinrich Senior Consultant Clinical Oncologist Department of Radiotherapy and Oncology Innlandet Hospital Trust, Norway
Date: 10 May 2023
Tags: Treatment landscape
QoL in mRCC clinical trials
Speaker: Interview with Professor David Cella.
Date: 10 November 2022
Tags: Quality of Life
Case experiences with combination therapy with cabozantinib + nivolumab as first-line treatment
Speaker: Interview with Professor Viktor Grünwald.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy
Long-Term effectiveness results of CheckMate-9ER
Speaker: Interview with Professor Toni K. Choueiri.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy
Timing of the treatment and patient stratification
Speaker: Interview with Professor Daniel Heng.
Date: 2 August 2022
Tags: Treatment timing and patient stratification
First-line combination treatments available for renal cell carcinoma
Speaker: Interview with Professor Sumanta Kumar Pal.
Date: 2 August 2022
Tags: Treatment landscape, First line systemic therapy
Quality of life and Patient-Reported Outcome Measures
Speaker: Interview with Professor David Cella.
Date: 2 August 2022
Tags: Quality of Life
Nivolumab + Cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1L
IPSEN and Bristol Myers Squibb webinar.
Speaker: Petri Bono, Viktor Grünwald, MD and Thomas Powles MBBS, MRCP, MD.
Date: 12 October 2021
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy
Rationale for combinations with CPI
Speaker: Katarina Puco, Senior Consultant Oncologist. Lovisenberg Diaconal Hospital Norway.
Date: 9 September 2021
Tags: Treatment landscape, First line systemic therapy
How can we help the patient to stay on treatment
Manuela Schmidinger. Medical University of Vienna, Austria.
Date: 29 April 2021
Tags: AE management
What is Renal Cell Carcinoma
By Martin Johansson, Professor in Pathology Sahlgrenska University Hospital/ Gothenburg university
Date: 31 March 2021
Tags: Pathology